Evidence map›Paper›PMID 42609219›Full record

ArticleFrontiers in pharmacology2026

Bioresponsive gelatin-coated silk fibroin nanoparticles enhance roxadustat therapy in experimental pulmonary fibrosis.

Elsayed A Elmorsy, Sameh Saber, Abdulaziz A Alsalloom, Abdullah Al-Nafeesah, Mostafa M Khodeir, Abdullah Alolayan, Adel Alhomaidi, Mohammed Alorini, Mohamed R Abdel-Hamed, Maha M Amer and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Elsayed A ElmorsyDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia.
Sameh SaberDepartment of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Mansoura, Egypt.
Abdulaziz A AlsalloomDepartment of Pathology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Abdullah Al-NafeesahDepartment of Pediatrics, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Mostafa M KhodeirDepartment of Pathology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Abdullah AlolayanDepartment of Pediatrics, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Adel AlhomaidiDepartment of Pathology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Mohammed AloriniDepartment of Pathology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Mohamed R Abdel-HamedDepartment of Anatomy and Histology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Maha M AmerDepartment of Anatomy and Histology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Huda EltayebDepartment of Basic Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Syed Suhail AhmedDepartment of Microbiology and Immunology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Noura El Adle KhalafDepartment of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Eman HamzaDepartment of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Ebtehal M Abdel-AalDepartment of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Abdelrahman El-SayedFaculty of Medicine, Damietta University, New Damietta, Egypt.
Ahmed Y KiraDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) requires delivery strategies that improve drug residence within lung tissue while limiting systemic exposure. Herein, roxadustat-loaded silk fibroin nanoparticles (RXS-SKNPs) were developed and coated with gelatin (GT) to produce an MMP-2-responsive pulmonary delivery platform. RXS-SKNPs were prepared by desolvation-assisted nanoprecipitation, followed by GT coating via electrostatic interactions. The optimized GT-RXS-SKNPs showed an increase in particle size from 145.72 ± 2.74 nm to 194.26 ± 2.94 nm, a zeta-potential shift from -30.28 ± 1.01 mV to -15.19 ± 2.38 mV, and an entrapment efficiency of 72.11% ± 0.81%. FTIR analysis and the increased surface-accessible amino-group signal confirmed GT coating and RXS incorporation. GT-RXS-SKNPs exhibited MMP-2-triggered colloidal remodeling and enzyme-responsive release, with cumulative RXS release increasing to 59.93% ± 1.30% after 24 h under MMP-2 exposure compared with 43.70% ± 1.32% in enzyme-free medium. Release followed anomalous non-Fickian behavior, indicating combined diffusion and GT shell erosion/relaxation.

Indexed as

gelatin coatingMMP-2-responsive deliverypulmonary fibrosisroxadustatsilk fibroin nanoparticles

Identifiers

PMID42609219
PMCPMC13477923

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.